- Home
- IREN vs NBIX Comparison
IREN vs NBIX Comparison
Compare IREN & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IREN | NBIX |
|---|---|---|
| Founded | 2018 | 1992 |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.9B | 13.2B |
| IPO Year | 2021 | 1996 |
Fundamental Metrics
Financial Performance| Metric | IREN | NBIX |
|---|---|---|
| Price | $47.93 | $132.87 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 22 |
| Target Price | $62.50 | ★ $180.82 |
| AVG Volume (30 Days) | ★ 27.9M | 950.3K |
| Earning Date | 05-13-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 234.48 | 41.95 |
| EPS | 0.68 | ★ 4.67 |
| Revenue | ★ $501,023,000.00 | $161,626,000.00 |
| Revenue This Year | $104.58 | $22.85 |
| Revenue Next Year | $200.20 | $10.36 |
| P/E Ratio | $70.31 | ★ $27.47 |
| Revenue Growth | 167.65 | ★ 977.51 |
| 52 Week Low | $5.46 | $98.95 |
| 52 Week High | $76.87 | $160.18 |
Technical Indicators
Market Signals| Indicator | IREN | NBIX |
|---|---|---|
| Relative Strength Index (RSI) | 64.75 | 54.14 |
| Support Level | $38.18 | $124.29 |
| Resistance Level | $49.15 | $136.23 |
| Average True Range (ATR) | 3.16 | 4.21 |
| MACD | 1.65 | 0.12 |
| Stochastic Oscillator | 89.26 | 85.22 |
Price Performance
Historical ComparisonAbout IREN Iris Energy Limited
IREN Ltd is engaged in data center business powering the future of Bitcoin, AI and beyond utilizing renewable energy. Bitcoin mining operations generate revenue by earning Bitcoin through a combination of Block rewards and transaction fees from the operation of its Bitcoin miners and exchanging these Bitcoin for fiat currencies such as USD or CAD.
About NBIX Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.